Inovio Projects Cash Runway Into Late 2027 Ahead of VOCERYQ Launch

Inovio Pharmaceuticals expects its current financial resources to fund planned operations into late Q4 2027, extending its projected cash runway beyond the planned commercial launch of VOCERYQ, its treatment for adults with recurrent respiratory papillomatosis (RRP).

The forecast includes $80.5 million in net proceeds from a public offering that closed Nov. 9 and $10.9 million from warrant exercises received after Sept. 30 through Nov. 9. It also assumes about $21 million in operational net cash burn during Q4 2026.

Inovio held $48.4 million in cash, cash equivalents and short-term investments as of Sept. 30. That period-end balance is separate from the later offering and warrant proceeds included in the forecast. The projection excludes VOCERYQ revenue and any future fundraising, and depends on assumptions about operations and commercialization costs.

The U.S. Food and Drug Administration approved VOCERYQ on Oct. 30 to reduce surgery frequency in adults with RRP under its accelerated approval program. Surgery to remove papillomas is a standard RRP treatment, and the growths often return.

Inovio expects VOCERYQ to be available to order and ship about 60 days after its approval and plans a full commercial launch in Q1 2027. It also plans to apply for conditional marketing authorization in Europe before the end of 2026.

The company cautioned that its current financial resources may not be sufficient to support planned operations beyond late Q4 2027 without additional financing. Inovio reported a $38 million working capital deficit as of Sept. 30. Its runway estimate relies on assumptions, including VOCERYQ launch and commercialization costs, that may change.